{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:02:44Z","timestamp":1790096564438,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xops.2026.101300","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:38:42Z","timestamp":1782319122000},"page":"101300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-Dose Atropine for Pediatric Myopia: First-Year Progression as a Risk-Stratification and Management Signal"],"prefix":"10.1016","volume":"6","author":[{"given":"Soh Youn","family":"Suh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karenna","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-0337","authenticated-orcid":false,"given":"Robert A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101300_bib1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archophthalmol.2009.303","article-title":"Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004","volume":"127","author":"Vitale","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101300_bib3","first-page":"10","article-title":"Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia","volume":"138","author":"Haarman","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/iovs.62.5.5","article-title":"International Myopia Institute (IMI) Pathologic Myopia","volume":"62","author":"Ohno-Matsui","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101300_bib5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ophtha.2010.01.020","article-title":"Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101300_bib6","first-page":"639","article-title":"High myopia as risk factor for the 10-year incidence of open-angle glaucoma in the Beijing Eye Study","volume":"129","author":"Wang","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101300_bib7","first-page":"481","article-title":"The economic and societal impact of myopia and high myopia","volume":"60","author":"Naidoo","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101300_bib8","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04183","article-title":"Lifetime cost-effectiveness of myopia control intervention for the children population","volume":"14","author":"So","year":"2024","journal-title":"J Glob Health"},{"key":"10.1016\/j.xops.2026.101300_bib9","first-page":"839","article-title":"Cost-Effectiveness analysis of myopia progression interventions in children","volume":"141","author":"Agyekum","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101300_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101300_bib12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib14","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/aos.15761","article-title":"Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population","volume":"102","author":"Loughman","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ceo.13736","article-title":"Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: rationale, methodology and participant baseline characteristics","volume":"48","author":"Lee","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","article-title":"A 3-year randomized clinical trial of MiSight lenses for myopia control","volume":"96","author":"Chamberlain","year":"2019","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.xops.2026.101300_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2020.10834","article-title":"Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial","volume":"324","author":"Walline","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2026.101300_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10384-018-0616-3","article-title":"Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial","volume":"62","author":"Kanda","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1167\/iovs.61.5.53","article-title":"Defocus incorporated multiple segments spectacle lenses changed the relative peripheral refraction: a 2-year randomized clinical trial","volume":"61","author":"Zhang","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101300_bib20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/opo.13548","article-title":"Comparative evaluation of different (peripheral defocus based) spectacle designs in preventing myopia progression: a double-blinded randomised clinical trial","volume":"45","author":"Gupta","year":"2025","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.xops.2026.101300_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ajo.2026.03.007","article-title":"Spherical equivalent refraction versus axial length for monitoring childhood myopia and estimating disease risk: a systematic review and meta-analysis","volume":"286","author":"Clark","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101300_bib22","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/opo.13379","article-title":"Can we really distinguish \u201cresponders\u201d from \u201cnon-responders\u201d to myopia control interventions?","volume":"44","author":"Brennan","year":"2024","journal-title":"Ophthalmic Physiol Opt"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:22:26Z","timestamp":1789464146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666914526002381"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101300","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Atropine for Pediatric Myopia: First-Year Progression as a Risk-Stratification and Management Signal","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101300"}}